Salamanca woman jailed on murder, other charges
Breaking News
Salamanca woman jailed on murder, other charges
November 1, 2025
SALAMANCA — A city woman is facing murder and other felony charges after a death on River Street on Friday morning. The Salamanca Police Department re...
Home Online Features Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Press Releases
Novartis Pharmaceuticals Corporation, Astex Pharmaceuticals  
October 24, 2024

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated by the FDA1Recommendation comes

logo salamanca press

Salamanca Press

email salamanca press
Local & Social